Arkema
France · FR0010313833 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue −5.0% in the year to Dec 31, 2025, on the year before.
- Is it a good business?To watch
- It earned 0.9% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Fair
- Equity is 49% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
€9.1B
revenue
3.2%
operating margin
€63M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €11.6B | €9.5B | €9.5B | €9.1B |
| Operating profit | €1.3B | €681M | €586M | €288M |
| Net profit to shareholders | €965M | €418M | €354M | €63M |
| Earnings per share | €12.81 | €5.39 | €4.51 | €0.52 |
| Dividend per share | n/a | €3.40 | n/a | €3.60 |
| Cash from operations | €1.5B | €1.3B | €1.1B | €997M |
| Cash | €1.6B | €2.0B | €2.0B | €2.2B |
| Total assets | €13.5B | €14.5B | €15.2B | €14.2B |
| Equity | €7.3B | €7.5B | €7.8B | €7.0B |
What they do
In the company's own words, from the annual report.
Chimie de Spécialités et des Matériaux Avancés
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.